Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients

Rosalba Torrisi, Stefano Parodi, Vincenzo Fontana, Gabriella Rondanina, Franca Formelli, Alberto Costa, Francesco Boccardo, Andrea Decensi

Research output: Contribution to journalArticlepeer-review

Abstract

Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.

Original languageEnglish
Pages (from-to)507-510
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume3
Issue number6
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients'. Together they form a unique fingerprint.

Cite this